Stress-overcoming behaviour of women with minor cardiac abnormalities

The purpose of this research was to determine stress-overcoming behaviour of women with minor cardiac abnormalities considering abnormality intensity. With the help of Toronto Alexithymia Scale, E. Heim`s system and S. Subbotin`s test 122 young women with different manifestation rates of the heart connective tissue dysplasia (minimal – basic group and moderate - comparison group) were examined (average age –21,46 ± 2,12 years). Significant dominance of adaptive coping strategies in all spheres was revealed when studying of stress-overcoming behaviour of healthy women with minor cardiac abnormalities of minimal intensity. Women of the comparison group used maladaptive coping-strategies in emotional and behavioural spheres more often comparing with clinically healthy women of the basic group. Significantly lower level of the stress resistance and higher alexithymia level were determined in the observed group with minor cardiac abnormalities of moderate intensity which has chosen maladaptive emotional and behavioural coping-strategies. The results are appropriate to consider for personalized arrangements for prevention of cardiovascular complications in patients with heart connective tissue dysplasia syndrome

A Cherenkov imager for charge measurements of Nuclear Cosmic Rays in the CREAM II instrument

A proximity focusing Cherenkov imager for the charge measurement of nuclear cosmic rays in the CREAM II instrument, called CHERCAM, is under construction. This imager consists of a silica aerogel radiator plane facing a detector plane equipped with standard photomultipliers. The two planes are separated by a minimal ring expansion gap. The Cherenkov light yield is proportional to the squared charge of the detected particle. The expected relative light collection accuracy is in the few percents range. It should lead to single element separation over the range of nuclear charge Z of main interest 1 $leq$ Z $<$\approx$ 26

In-beam tests of the AMS RICH prototype with 20 A GeV/c secondary ions

Abstract A prototype of the AMS Cherenkov imager (RICH) has been tested by means of a low intensity 20 GeV /c per nucleon ion beam coming from the fragmentation of a primary beam of Pb ions. Data have been collected for charges

Assessment of Actinobacteria Role in Activity of Deep-water Endemic Amphipod Species Belonging to the Genus Ommatogammarus

The aim of present study was to reveal the associations between the actinobacteria strains and Lake Baikal deep-water endemic amphipods. During the study forty-two actinobacteria strains were isolated from the amphipods belonging to the genus Ommatogammarus (O. albinus and O. flavus) which were caught from the depth 80 – 200 m. The analysis of part of the gene 16S rRNA revealed that obtained strains belonging to the genera Streptomyces, Micromonospora, and Pseudonocardia. The results of the investigation display that actinobacteria that produce antimicrobial compounds inhabit the organism of amphipods from the Ommatogammarus genus. It is assumed that actinobacteria might effect the metabolism of deep-water amphipod-scavengers. Besides, actinobacteria obtained from Lake Baikal endemic amphipods have potential pharmaceutical applications as the source of antibiotics. They also enlarge our understanding of relationships between microorganisms and endemic amphipods

Secondary Metabolites Detected in Deep-Water Endemic Amphipods of Lake Baikal: Bacterial or Crustacean Origin?

The aim of the study was to conduct a dereplication analysis of crude extract of deepwater Baikal’s endemic amphipod species, Ommatogammarus albinus. Detected masses provide some evidence that amphipod’s extract might contain both host and microbiota secondary metabolites. Some of the masses correspond with known structures isolated from eubacteria. Also, two compounds did not match with any registered natural products from the database Dictionary of Natural Products. Those findings allow suggesting that Baikal’s endemics and their microbiota are promising sources of novel natural products

Haemolymph of Cold-Adapted Baikal Endemic Amphipods as a Promising Source for Screening of Novel Natural Products

The aim of this study was to assess the possibility to use Baikal endemic amphipods as a source for screening of novel natural products. Analysis of amphipod’s E. verrucosus hemolymph by HPLC-MS was performed for the first time. A number of natural products with new molecular mass for Baikal endemic macroinvertebrates were found. We found a compound as chrysin by comparison of MS1, MS2 profiles and molecular mass of natural products registered in Dictionary of Natural Products and MZ-cloud databases. Also, we found new compound with mass 493.80277 Da, circulating in the amphipod’s hemolymph

Culturable Actinobacteria Associated with Baikal Algae: Diversity and Antimicrobial Activity

The aim of the study was to assess the biodiversity of culturable strains of actinobacteria isolated from freshwater Baikal algae Draparnaldioides baicalensis and to assess the antimicrobial activity of compounds against Gram-positive bacteria. In the course of this study, we isolated both widespread strains of the genus Streptomyces, and rare representatives of the genus Saccharopolyspora, Nonomuraea, Rhodococcus and Micromonospora. We demonstrated that the strains produce natural products with antimicrobial activity. Considering the large number of rare and active strains associated with the endemic algae D. baicalensis, we shown that these microorganisms have a value for biomedical and biotechnological development and to discovery of new natural compounds, including antibiotics

Исследование безопасности введения 13-валентной пневмококковой конъюгированной вакцины и поствакцинальный иммунный ответ к серотипам Streptococcus pneumoniae у взрослых больных с бронхиальной астмой и хронической обструктивной болезнью легких

Background. Vaccination against pneumococcal infection is one of the priorities in improving the quality of treatment and prevention measures in adults with various pathologies. The effectiveness of vaccination is directly related to the individuals ability to form an adequate specific immunity. Aims the aim of the study was to assess the level of post-vaccination antibodies to capsular polysaccharides of S. pneumoniae in adult patients with bronchial asthma (BA) or chronic obstructive pulmonary disease (COPD) after administration of 13-valent conjugated pneumococcal vaccine (PCV13). Materials and methods. The ELISA method was used to determine the level of IgG antibodies to 12 capsular polysaccharides serotypes 1, 3, 4, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F of S. pneumoniae that are part of PCV13, and 2 serotypes 9N, 15B that are not part of the vaccines using research test systems developed on the basis of the I.I. Mechnikov Research Institute of Vaccines and Sera. Groups of adult patients 32 patients with BA and 33 with COPD who received basic treatment according to accepted international standards. The comparison group consists of 20 healthy patients who do not have comorbidities. In patients, vaccination was performed outside the acute period of the disease using PCV13. Results. Vaccination of PCV13 patients with BA and COPD does not lead to the development of exacerbations of the underlying disease, while unusual symptoms in the post-vaccination period, provided for by the drugs instructions, can rarely develop. A comparative analysis of changes in IgG antibodies conducted after 6 weeks relative to the initial level of IgG antibodies to S. pneumoniae capsular polysaccharides in adult patients and healthy vaccinated PCV13 showed the same increase in specific antibodies to 12 serotypes of pneumococcus. The difference was found only in relation to IgG antibodies to a mixture of polysaccharides included in the PCV13 vaccine, which were registered higher in patients with BA and COPD in the post-vaccination period (p 0.001) than in healthy patients. Conclusions. PCV13 vaccination of patients with BA and COPD is safe and is accompanied by the synthesis of IgG antibodies to capsular polysaccharides serotypes of S. pneumoniae similarly to the healthy group.Обоснование. Одним из приоритетных направлений в улучшении качества лечебно-профилактических мероприятий у взрослого населения с различными патологиями является вакцинация против пневмококковой инфекции. Эффективность вакцинации находится в прямой зависимости от способности индивидуума к формированию адекватного специфического иммунитета. Цель исследования оценить уровень поствакцинальных антител к капсульным полисахаридам S. pneumoniae у взрослых больных бронхиальной астмой (БА) и хронической обструктивной болезнью легких (ХОБЛ) после введения 13-валентной конъюгированной пневмококковой вакцины (ПКВ13). Методы. Методом ИФА проведено определение уровня IgG-антител к 12 капсульным полисахаридам (КПС) серотипов 1, 3, 4, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F S. pneumoniae, входящим в состав ПКВ13, и 2 серотипам (9N, 15В), не входящим в него, с использованием исследовательских тест-систем, разработанных на базе ФГБНУ НИИ вакцин и сывороток им. И.И. Мечникова. Группы взрослых больных 32 пациента, страдающих БА, и 33 пациента с ХОБЛ, которые получали основное лечение согласно принятым международным стандартам. Группа сравнения 20 здоровых, не имеющих сопутствующих заболеваний. У больных вакцинация проводилась вне острого периода заболевания с использованием ПКВ13. Результаты. Вакцинация ПКВ13 пациентов с БА и ХОБЛ не приводит к развитию обострений основного заболевания, при этом редко могут развиться необычные явления в поствакцинальном периоде, предусмотренные инструкцией к препарату. Сравнительный анализ изменений уровней поствакцинальных антител, проведенный через 6 нед, относительно исходного уровня IgG-антител к капсульным полисахаридам S. pneumoniae у взрослых больных и здоровых привитых ПКВ13 показал одинаковое нарастание специфических антител к 12 серотипам пневмококка. Различие выявлено только в отношении IgG-антител к смеси полисахаридов, входящих в состав вакцины ПКВ13, которые у пациентов с БА и ХОБЛ в поствакцинальном периоде регистрировались в более высоких титрах (p 0,001), чем у здоровых лиц. Заключение. Вакцинация ПКВ13 больных с БА и ХОБЛ безопасна и сопровождается синтезом IgG-антител к капсульным полисахаридам серотипов S. pneumoniae